Wilkinson Global Asset Management LLC Has $72.75 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Wilkinson Global Asset Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 279,105 shares of the medical research company's stock after selling 6,077 shares during the quarter. Amgen accounts for about 4.5% of Wilkinson Global Asset Management LLC's investment portfolio, making the stock its 7th largest holding. Wilkinson Global Asset Management LLC owned approximately 0.05% of Amgen worth $72,746,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Pathway Financial Advisers LLC grew its position in Amgen by 33,125.4% in the third quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock valued at $1,437,115,000 after acquiring an additional 4,446,757 shares in the last quarter. International Assets Investment Management LLC grew its position in shares of Amgen by 6,812.4% during the third quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company's stock worth $8,130,610,000 after buying an additional 2,486,882 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Amgen by 561.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,539,733 shares of the medical research company's stock worth $496,117,000 after buying an additional 1,306,982 shares in the last quarter. Van ECK Associates Corp grew its position in shares of Amgen by 263.8% during the fourth quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company's stock worth $270,699,000 after buying an additional 753,147 shares in the last quarter. Finally, Nordea Investment Management AB lifted its stake in Amgen by 40.7% during the fourth quarter. Nordea Investment Management AB now owns 2,338,665 shares of the medical research company's stock worth $609,526,000 after purchasing an additional 676,598 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AMGN shares. Wolfe Research started coverage on Amgen in a research note on Friday, November 15th. They set a "peer perform" rating on the stock. Redburn Partners reduced their price objective on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Jefferies Financial Group restated a "buy" rating and set a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. Bank of America raised their price objective on Amgen from $256.00 to $275.00 and gave the stock an "underperform" rating in a research note on Thursday, February 6th. Finally, William Blair reiterated an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Amgen has an average rating of "Hold" and a consensus price target of $314.09.

Insider Buying and Selling at Amgen

In related news, EVP Murdo Gordon sold 8,771 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the sale, the executive vice president now owns 44,186 shares of the company's stock, valued at approximately $13,025,590.94. The trade was a 16.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 in the last 90 days. 0.69% of the stock is currently owned by corporate insiders.

Amgen Price Performance

NASDAQ:AMGN traded up $5.08 during mid-day trading on Friday, reaching $303.01. 3,260,757 shares of the stock were exchanged, compared to its average volume of 3,124,757. The business has a fifty day moving average price of $276.27 and a 200 day moving average price of $300.59. The firm has a market capitalization of $162.78 billion, a PE ratio of 40.13, a PEG ratio of 2.55 and a beta of 0.56. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts expect that Amgen Inc. will post 20.6 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.14%. The ex-dividend date is Friday, February 14th. This is a boost from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.